Development challenges for medicines for central nervous system disorders

An analysis of over 100 applications submitted between 1995 and 2014 to the European Medicines Agency (EMA) shows that various challenges can arise in the development of medicines meant to treat central nervous system (CNS) disorders, and highlights the importance of an appropriate design of early-stage clinical trials for future success in the development. This analysis of the applications for medicines in the fields of psychiatry or neurology, led by staff members of EMA, is published in Nature Reviews Drug Discovery. Research into medicines for CNS is complex, with a higher rate of failure during the clinical development of these